Clinical trials

  • Durvalumab for Hepatocellular carcinoma
  • Efgartigimod alfa for Generalized myasthenia gravis|Myasthenia gravis
  • PLATELET CONCENTRATE for Genitourinary syndrome of menopause
  • GEMCITABINE HYDROCHLORIDE for High-risk non-muscle-invasive bladder cancer | Bladder cancer
  • Platelet concentrate for Dry Eye Disease
  • ROMIPLOSTIM for Chemotherapy-induced thrombocytopenia | Non-small cell lung cancer | Ovarian cancer | Breast cancer
  • Infliximab for Crohn's disease|Inflammatory bowel disease, unclassified (IBD-U)
  • Erdafitinib for Non-muscle invasive bladder cancer (intermediate-risk) | FGFR gene alterations
  • KD050 for Advanced solid tumors | Non-small cell lung cancer | Hepatocellular carcinoma | Gastric cancer | Gastroesophageal junction adenocarcinoma | Colorectal cancer | Melanoma | Renal cell carcinoma | Malignant pleural mesothelioma | Esophageal squamous cell carcinoma
  • ACP-204 TARTRATE for Alzheimer's disease psychosis | Alzheimer's disease
  • PRP (platelet-rich plasma) for Knee osteoarthritis
  • PRASINEZUMAB for Early Parkinson's disease